TPTX » Topics » We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our research and development programs or commercialization efforts.

This excerpt taken from the TPTX DEF 14A filed Jun 19, 2009.

We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

 

   

the rate of progress and cost of clinical trials;

 

   

the scope of our clinical trials and other development activities;

 

   

the prioritization and number of clinical development programs we pursue;

 

   

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

 

   

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

   

the costs and timing of regulatory approvals;

 

   

the costs of goods and manufacturing expenses; and

 

   

the costs of establishing or contracting for sales and marketing capabilities.

We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that our immediate funding needs or future additional funding needs will be available on acceptable terms, or at all. If the near term funds that we need to continue operations do not become available, we may be required to file for bankruptcy, cease operations or liquidate and dissolve the Company.

This excerpt taken from the TPTX 10-Q filed May 1, 2009.

We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

 

   

the rate of progress and cost of clinical trials;

 

   

the scope of our clinical trials and other development activities;

 

   

the prioritization and number of clinical development programs we pursue;

 

   

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

 

   

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

   

the costs and timing of regulatory approvals;

 

   

the costs of goods and manufacturing expenses; and

 

   

the costs of establishing or contracting for sales and marketing capabilities.

We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that our immediate funding needs or future additional funding needs will be available on acceptable terms, or at all. If the near term funds that we need to continue operations do not become available, we may be required to file for bankruptcy, cease operations or liquidate and dissolve the Company.

These excerpts taken from the TPTX 10-K filed Mar 27, 2009.

We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our discovery and development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

 

   

the rate of progress and cost of clinical trials;

 

   

the scope of our clinical trials and other discovery and development activities;

 

   

the prioritization and number of clinical development and discovery programs we pursue;

 

   

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

 

   

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

   

the costs and timing of regulatory approvals;

 

   

the costs of goods and manufacturing expenses; and

 

   

the costs of establishing or contracting for sales and marketing capabilities.

We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as

 

18


Table of Contents

through interest income earned on cash balances. We cannot be certain that our immediate funding needs or future additional funding needs will be available on acceptable terms, or at all. If the near term funds that we need to continue operations do not become available, we may be required to cease operations, seek protection under the provisions of the U.S. Bankruptcy Code or liquidate and dissolve the Company.

We will need substantial additional
funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our discovery and development programs or commercialization efforts.

STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%">We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as
a result of, many factors, including:

 







  

the rate of progress and cost of clinical trials;

 







  

the scope of our clinical trials and other discovery and development activities;

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

the prioritization and number of clinical development and discovery programs we pursue;

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

the costs and timing of regulatory approvals;

 







  

the costs of goods and manufacturing expenses; and

 







  

the costs of establishing or contracting for sales and marketing capabilities.

FACE="Times New Roman" SIZE="2">We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through
public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as

 


18







Table of Contents



through interest income earned on cash balances. We cannot be certain that our immediate funding needs or future additional funding needs will be available
on acceptable terms, or at all. If the near term funds that we need to continue operations do not become available, we may be required to cease operations, seek protection under the provisions of the U.S. Bankruptcy Code or liquidate and dissolve
the Company.

This excerpt taken from the TPTX 10-Q filed Nov 12, 2008.

*We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

 

   

the rate of progress and cost of clinical trials;

 

   

the scope of our clinical trials and other development activities;

 

   

the prioritization and number of clinical development programs we pursue;

 

   

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

 

   

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

   

the costs and timing of regulatory approvals;

 

   

the costs of goods and manufacturing expenses; and

 

   

the costs of establishing or contracting for sales and marketing capabilities.

The current economic crisis and its impact on the stock markets will most likely have a negative impact on our ability to raise additional needed capital on terms that are favorable to the company or at all. We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our development programs or commercialization efforts.

This excerpt taken from the TPTX 10-Q filed Aug 12, 2008.

We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our discovery and development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

 

   

the rate of progress and cost of clinical trials;

 

14


Table of Contents
   

the scope of our clinical trials and other discovery and development activities;

 

   

the prioritization and number of clinical development and discovery programs we pursue;

 

   

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

 

   

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

   

the costs and timing of regulatory approvals;

 

   

the costs of goods and manufacturing expenses; and

 

   

the costs of establishing or contracting for sales and marketing capabilities.

We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our discovery and development programs or commercialization efforts.

This excerpt taken from the TPTX 10-Q filed May 13, 2008.
We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our discovery and development programs or commercialization efforts.

 

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

 

·      the rate of progress and cost of clinical trials;

 

·      the scope of our clinical trials and other discovery and development activities;

 

·      the prioritization and number of clinical development and discovery programs we pursue;

 

·      the terms and timing of any collaborative, licensing and other arrangements that we may establish;

 

·      the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

·      the costs and timing of regulatory approvals;

 

·      the costs of goods and manufacturing expenses; and

 

·      the costs of establishing or contracting for sales and marketing capabilities.

 

We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our discovery and development programs or commercialization efforts.

 

These excerpts taken from the TPTX 10-K filed Mar 31, 2008.

We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our discovery and development programs or commercialization efforts.

        We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

    the rate of progress and cost of clinical trials;

    the scope of our clinical trials and other discovery and development activities;

    the prioritization and number of clinical development and discovery programs we pursue;

    the terms and timing of any collaborative, licensing and other arrangements that we may establish;

    the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

    the costs and timing of regulatory approvals;

    the costs of goods and manufacturing expenses; and

19


    the costs of establishing or contracting for sales and marketing capabilities.

        We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our discovery and development programs or commercialization efforts.

We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our
discovery and development programs or commercialization efforts.



        We
will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors,
including:





    the
    rate of progress and cost of clinical trials;


    the
    scope of our clinical trials and other discovery and development activities;


    the
    prioritization and number of clinical development and discovery programs we pursue;


    the
    terms and timing of any collaborative, licensing and other arrangements that we may establish;


    the
    costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;


    the
    costs and timing of regulatory approvals;


    the
    costs of goods and manufacturing expenses; and


19












    the
    costs of establishing or contracting for sales and marketing capabilities.



        We
do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to
satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash
balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or
eliminate one or more of our discovery and development programs or commercialization efforts.



This excerpt taken from the TPTX 10-Q filed Nov 14, 2007.
We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our research and development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

      the rate of progress and cost of clinical trials;

      the scope of our clinical trials and other discovery and development activities;

      the prioritization and number of clinical development and discovery programs we pursue;

 

21



 

      the terms and timing of any collaborative, licensing and other arrangements that we may establish;

      the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

      the costs and timing of regulatory approvals;

      the costs of goods and manufacturing expenses; and

      the costs of establishing or contracting for sales and marketing capabilities.

We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of its research and development programs or commercialization efforts.

This excerpt taken from the TPTX 10-Q filed Aug 14, 2007.
We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our research and development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

·      the rate of progress and cost of clinical trials;

·      the scope of our clinical trials and other discovery and development activities;

·      the prioritization and number of clinical development and discovery programs we pursue;

·      the terms and timing of any collaborative, licensing and other arrangements that we may establish;

·      the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

·      the costs and timing of regulatory approvals;

·      the costs of goods and manufacturing expenses; and

·      the costs of establishing or contracting for sales and marketing capabilities.

18




We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of its research and development programs or commercialization efforts.

This excerpt taken from the TPTX 10-Q filed May 14, 2007.
We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our research and development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

·         the rate of progress and cost of clinical trials;

·    the scope of our clinical trials and other research and development activities;

·         the prioritization and number of clinical development and research programs we pursue;

·         the terms and timing of any collaborative, licensing and other arrangements that we may establish;

·         the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

·         the costs and timing of regulatory approvals;

·         the costs of goods and manufacturing expenses; and

·         the costs of establishing or contracting for sales and marketing capabilities.

We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of its research and development programs or commercialization efforts.

This excerpt taken from the TPTX 10-K filed Mar 29, 2007.

We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our research and development programs or commercialization efforts.

We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

·       the rate of progress and cost of clinical trials;

26




·       the scope of our clinical trials and other research and development activities;

·       the prioritization and number of clinical development and research programs we pursue;

·       the terms and timing of any collaborative, licensing and other arrangements that we may establish;

·       the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

·       the costs and timing of regulatory approvals;

·       the costs of goods and manufacturing expenses; and

·       the costs of establishing or contracting for sales and marketing capabilities.

We do not anticipate that we will generate significant continuing revenue for several years, if at all. Until we can generate significant continuing revenue, if ever, we expect to satisfy our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of its research and development programs or commercialization efforts.

This excerpt taken from the TPTX 10-Q filed Nov 9, 2006.

*We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate its research and development programs or commercialization efforts.

          We will need to raise substantial additional capital in the future and additional funding requirements will depend on, and could increase significantly as a result of, many factors, including:

 

 

 

• the rate of progress and cost of clinical trials;

 

 

 

• the scope of our clinical trials and other research and development activities;

 

 

 

• the prioritization and number of clinical development and research programs we pursue;

 

 

 

• the terms and timing of any collaborative, licensing and other arrangements that we may establish;

 

 

 

• the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

 

 

• the costs and timing of regulatory approvals; and

 

 

 

• the costs of establishing or contracting for sales and marketing capabilities.

          We do not anticipate that we will generate significant continuing revenues for several years, if at all. Until we can generate significant continuing revenues, if ever, we expect to satisfy its future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development programs or commercialization efforts.

"We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our research and development programs or commercialization efforts." elsewhere:

DEXTERA SURGICAL INC (CRDC)
Icagen (ICGN)
Molecular Templates, Inc. (THLD)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki